Lupus & antiphospholipid syndrome
Disease progression in patients with systemic lupus erythematosus: an analysis of the SLE Prospective Observational Cohort Study (SPOCS)
Authors' conclusion
In the SPOCS cohort, disease activity was stable or reduced over time, but treatment target attainment was low and organ damage increased. At month 36, there were no clear differences by baseline IFNGS.
Study context
- Population
- Adults with moderate to severe SLE activity receiving standard of care750 with IFN gene signature (IFNGS) status
- Participants
- 826 adults
- Exposure
- IFNGS-high vs IFNGS-low at baseline
- IFNGS-highn = 531
- IFNGS-lown = 219reference
- Outcome
- Disease progression (SLEDAI-2K, PGA, SELENA-SLEDAI flares, SLICC/ACR DI, DORIS remission/LLDAS) by baseline IFNGS
- Follow-up
- ≤36 months
Methodological detailsbiannual assessments for ≤36 months
- Biannual assessments for ≤36 months
Main finding
As reported in the abstract
SLEDAI-2K decreased from baseline to month 36, regardless of baseline IFNGS
9.8 ± 4.6-5.7 ± 7.7
≥1 flare by month 36
44.7%
183/409
Definition of Remission in SLE (DORIS) remission attained at any timepoint
<15%
Lupus Low Disease Activity State (LLDAS) attained at any timepoint
<20%
Observational data: associations, not effects.
Further findings
Baseline characteristics: age (years) and GC use · events/value = GC use
Age, mean ± SD (years) IFNGS-high 42.9 ± 13.6 · IFNGS-low 50.8 ± 12.9
- Baseline characteristics: age (years) and GC use — Time since SLE diagnosis, mean ± SD (years)
- 11.1 ± 9.2
- Baseline characteristics: age (years) and GC use — IFNGS-high at enrolment
- 70.8% (531/750)
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →